脫髮症市場 - 全球產業規模、佔有率、趨勢、機會、預測：治療方法、給藥途徑、最終用途、區域和競爭格局，2021-2031年

全球脫髮症市場預計將從 2025 年的 92.4 億美元成長到 2031 年的 151.2 億美元，複合年成長率為 8.55%。

脫髮症是一種自體免疫疾病，患者的免疫系統會攻擊毛囊，導致非疤痕性脫髮，脫髮範圍從局部斑塊到整個頭皮或身體的完全脫髮不等。該市場成長的主要驅動力是全球自體免疫疾病診斷率的上升，以及靶向Janus激酶 (JAK) 抑制劑近期獲得監管部門核准，這些藥物與傳統的全身療法相比，療效更佳。此外，患者權益倡導網路的加強顯著提高了公眾對該疾病的認知，並促進了早期治療性介入，從而有效地擴大了藥物研發的目標患者群體。

根據美國國家脫髮症的數據，到2024年，美國將有約680萬人受到斑禿的影響，凸顯了對可靠的長期治療方案的迫切需求。儘管市場成長潛力巨大，但仍面臨一個主要障礙：新型口服療法的高昂年費用。這些費用對報銷造成了重大障礙，並限制了患者的用藥，尤其是在醫療保險公司嚴格限制承保範圍的地區。

市場促進因素

新型Janus激酶 (JAK) 抑制劑療法的商業性核准正在改變市場格局，提高了治療傳統療法難以改善的重症病例的標準。這些標靶口服藥物透過抑制與毛囊發炎相關的特定免疫路徑發揮作用，為遭受廣泛性脫髮的患者提供了強力的治療選擇。例如，太陽製藥工業公司 (Sun Pharmaceutical Industries) 報告稱，美國食品藥物管理局(FDA) 於 2024 年 7 月核准了 Lexervi（度索替尼）用於治療成人重脫髮症患者。該批准基於臨床試驗結果，其中超過 30% 的受試者在 24 週後頭皮毛髮恢復率超過 80%。這項監管成就不僅證實了 JAK 抑制劑的治療效果，而且透過加速進一步的商業化和競爭產品的上市，迅速擴大了可用治療方法的範圍。

同時，自體免疫脫髮症在全球範圍內的日益普遍，擴大了目標患者群體，也加劇了對這些先進醫療干預措施的迫切需求。診斷技術的進步和公眾意識的提高，促使更多患者尋求醫療診斷，這直接推動了市場擴張。 2024年8月發表於《英國皮膚病學雜誌》的一項系統性綜述估計，經醫生診斷的脫髮症患病率約為普通人群的0.10%，凸顯了該疾病帶來的沉重負擔，亟需有效的管理。從產業財務趨勢可以看出，成功治療這個不斷成長的患者群體具有巨大的經濟價值。例如，2024年7月，Aclaris Therapeutics宣布接受其JAK抑制劑Olumiant未來特許權使用費的2,650萬美元預付款，這表明投資者對該治療領域的長期商業性前景充滿信心。

市場挑戰

新型口服療法帶來的沉重經濟負擔是限制脫髮症市場成長的主要阻礙因素。儘管標靶JAK抑制劑療效顯著，但其高昂的價格往往限制了公共和私人醫療保險的覆蓋範圍。保險公司通常將這些藥物歸類為處方藥，導致複雜的核准流程和患者高額的自付費用。這種經濟障礙直接降低了確診患者實際接受治療的比例，從而限制了生產者的獲利能力。

根據臨床經濟與評估研究所 (ICER) 的數據，預計到 2023 年，常用口服 JAK 抑制劑的年度批發採購成本將達到每位患者 49,000 至 50,000 美元。如此高的採購成本促使保險公司採用嚴格的合格標準，導致治療啟動延遲和長期用藥遵從性降低。因此，這些治療方法的高臨床需求與其經濟可及性之間的差距限制了處方總量，並阻礙了整體市場成長。

市場趨勢

監管機構核准青少年和兒童適應症的趨勢正在顯著擴大潛在患者群體，使其不再局限於傳統上主導主導地位的成年人群。製藥公司正積極尋求在較年輕年齡層中發揮臨床療效，以滿足青少年發病病例中尚未滿足的需求，這些病例通常病情更重，心理影響也更大。這項策略演變得到了近期兒童族群臨床結果的支持，這些結果正在推動適應症的擴大和納入更廣泛的處方清單。例如，美國國家脫髮症基金會2025年10月的數據顯示，在一項3期臨床試驗中，接受4毫Baricitinib脫髮症治療的重度斑禿青少年患者中，71%在52週時實現了頭皮和頭髮再生，這支持了全身性JAK抑製劑在該年齡層中的療效。

同時，長期維持治療通訊協定的採用已成為一項關鍵優先事項，相關人員強調持續的疾病管理而非暫時緩解。製造商正積極利用多年療效數據來證明治療效果的持久性，從而向支付方和監管機構證明長期使用昂貴的免疫調節劑的合理性。持續用藥可有效預防對治療有反應的患者出現復發，這項證據支持了長期治療的轉變。根據HCPLive在2025年9月報道，一項在歐洲皮膚病與性病學會（EADV）大會上發表的長期隨訪研究表明，接受利曲替尼治療12個月後毛髮顯著再生的患者中，約90%在持續治療36個月後仍保持了這種臨床改善。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球脫髮症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（藥物、療法）
  • 給藥途徑（口服、外用、注射）
  • 依最終用途（醫院、皮膚科診所、居家醫療機構）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美脫髮症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲脫髮症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區脫髮症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲脫髮症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲脫髮症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球脫髮症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• Merck & Co., Inc.
• GSK Plc
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• AstraZeneca Plc
• Abbott Laboratories Inc.
• Sun Pharmaceutical Industries Ltd.
• Eli Lilly and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Alopecia Areata Market is projected to expand from a valuation of USD 9.24 billion in 2025 to USD 15.12 billion by 2031, reflecting a compound annual growth rate of 8.55%. Alopecia areata represents an autoimmune disease where the immune system targets hair follicles, leading to non-scarring hair loss that varies from isolated patches to total scalp or body hair loss. This market growth is largely fueled by the rising rate of diagnoses for autoimmune disorders globally and the recent regulatory authorization of targeted Janus kinase (JAK) inhibitors, which have established superior efficacy benchmarks compared to conventional systemic therapies. Additionally, the strengthening network of patient advocacy organizations has substantially heightened disease awareness and facilitated earlier therapeutic engagement, effectively broadening the pool of patients available to pharmaceutical developers.

Data from the National Alopecia Areata Foundation indicates that in 2024, approximately 6.8 million people in the United States were affected by the condition, highlighting a significant need for reliable long-term management solutions. Despite this strong growth potential, the market faces a major obstacle in the form of the high annual pricing of new oral treatments. These costs create considerable hurdles regarding reimbursement and restrict patient access, particularly in geographic areas where healthcare payers enforce strict coverage limitations.

Market Driver

The commercial authorization of novel Janus kinase (JAK) inhibitor therapies is transforming the market by setting elevated standards of care for severe cases that previously resisted traditional systemic management. These targeted oral drugs work by blocking specific immune pathways associated with hair follicle inflammation, providing a powerful option for individuals suffering from extensive hair loss. For example, Sun Pharmaceutical Industries reported that in July 2024, the U.S. FDA granted approval for Leqselvi (deuruxolitinib) to treat adults with severe alopecia areata, based on clinical trials where over 30% of participants attained at least 80% scalp hair coverage after 24 weeks. This regulatory achievement not only confirms the therapeutic validity of JAK inhibitors but also stimulates further commercialization and the launch of competitive products that are swiftly broadening the range of available treatments.

At the same time, the increasing global prevalence of autoimmune hair loss conditions is enlarging the target patient population and fueling an urgent need for these sophisticated medical interventions. As diagnostic techniques advance and awareness spreads, a greater percentage of affected individuals are obtaining medical diagnoses, which directly supports market expansion. According to a systematic review published in the British Journal of Dermatology in August 2024, the global lifetime prevalence of physician-diagnosed alopecia areata is estimated at around 0.10% of the general population, underscoring a heavy disease burden that demands effective control. The high economic value attributed to successful treatments for this growing demographic is further demonstrated by sector financial activity; for instance, Aclaris Therapeutics announced in July 2024 that it received an upfront payment of $26.5 million for future royalty rights regarding the JAK inhibitor Olumiant, indicating robust investor faith in the long-term commercial prospects of this therapeutic category.

Market Challenge

The substantial financial burden linked to new oral therapies serves as a major constraint on the growth of the alopecia areata market. Although targeted Janus kinase inhibitors offer superior clinical results, their high pricing models often result in limited coverage policies from both public and private healthcare payers. Insurance providers frequently classify these drugs as specialty medications, which triggers complicated prior authorization requirements and imposes heavy out-of-pocket costs on patients. This economic barrier directly lowers the rate at which diagnosed patients convert into active users of these treatments, thereby curtailing the revenue potential for manufacturers.

According to the Institute for Clinical and Economic Review, the estimated annual wholesale acquisition cost for widely prescribed oral JAK inhibitors in 2023 fell between $49,000 and $50,000 per patient. Such high acquisition prices drive insurance companies to enforce strict eligibility criteria, which postpones the start of treatment and negatively impacts long-term adherence. As a result, the gap between the high clinical need for these therapies and their financial accessibility limits the total volume of prescriptions issued and hinders the overall growth trajectory of the market.

Market Trends

The regulatory movement toward including adolescent and pediatric indications is considerably expanding the potential patient base beyond the adult demographic that formerly dominated this sector. Pharmaceutical companies are actively seeking clinical validation for younger age groups to meet the significant unmet needs in early-onset cases, which frequently present with greater severity and psychological impact. This strategic evolution is supported by recent clinical achievements in pediatric groups, which are facilitating label expansions and broader formulary acceptance. For example, data from the National Alopecia Areata Foundation in October 2025 revealed that 52-week results from a Phase 3 trial demonstrated that 71% of adolescents with severe alopecia areata treated with 4 mg of baricitinib achieved successful scalp hair regrowth, underscoring the effectiveness of systemic JAK inhibitors for this younger population.

Simultaneously, the adoption of long-term maintenance therapy protocols is emerging as a key priority, with stakeholders emphasizing sustained disease management over temporary remission. Manufacturers are increasingly utilizing multi-year efficacy data to prove the durability of treatment responses, thereby validating the chronic prescription of expensive immunomodulators to payers and regulatory agencies. This shift toward a chronic care framework is backed by evidence showing that continuous dosing effectively prevents relapse in patients who respond to treatment. According to HCPLive in September 2025, long-term findings presented at the European Academy of Dermatology and Venereology Congress showed that roughly 90% of patients treated with ritlecitinib who attained significant hair regrowth by month 12 preserved this clinical improvement through 36 months of ongoing therapy.

Key Market Players

• Pfizer Inc.
• Merck & Co., Inc.
• GSK Plc
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• AstraZeneca Plc
• Abbott Laboratories Inc.
• Sun Pharmaceutical Industries Ltd.
• Eli Lilly and Company

Report Scope

In this report, the Global Alopecia Areata Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alopecia Areata Market, By Treatment

• Medications
• Therapies

Alopecia Areata Market, By Route of Administration

• Oral
• Topical
• Injection

Alopecia Areata Market, By End Use

• Hospitals
• Dermatology Clinics
• Homecare Settings

Alopecia Areata Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alopecia Areata Market.

Available Customizations:

Global Alopecia Areata Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alopecia Areata Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Medications, Therapies)
  • 5.2.2. By Route of Administration (Oral, Topical, Injection)
  • 5.2.3. By End Use (Hospitals, Dermatology Clinics, Homecare Settings)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Alopecia Areata Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Route of Administration
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Alopecia Areata Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Alopecia Areata Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Alopecia Areata Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By End Use

7. Europe Alopecia Areata Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Route of Administration
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Alopecia Areata Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Alopecia Areata Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Alopecia Areata Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Alopecia Areata Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Alopecia Areata Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By End Use

8. Asia Pacific Alopecia Areata Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Route of Administration
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Alopecia Areata Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Alopecia Areata Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Alopecia Areata Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Alopecia Areata Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Alopecia Areata Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Alopecia Areata Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Route of Administration
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Alopecia Areata Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Alopecia Areata Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Alopecia Areata Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End Use

10. South America Alopecia Areata Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Route of Administration
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Alopecia Areata Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Alopecia Areata Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Alopecia Areata Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Alopecia Areata Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. GSK Plc
• 15.4. Bayer AG
• 15.5. Dr. Reddy's Laboratories Ltd.
• 15.6. Viatris Inc.
• 15.7. AstraZeneca Plc
• 15.8. Abbott Laboratories Inc.
• 15.9. Sun Pharmaceutical Industries Ltd.
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer